ResultsIQ

ResultsIQ › Latest results › Metropolis Healthcare Limited

Metropolis Healthcare Limited Q3 FY26 results deck summary

NSE: METROPOLIS · BSE: 542650

Results deck of 4 Feb 2026, summarised by AI from the filing.

MHL Group Q3FY26 revenue ₹406 cr, up 25.8% YoY, with EBITDA margin 23.4% and PAT excluding exceptional item ₹51 cr.

Key takeaways

  1. Guidance Target a revenue CAGR of mid-teen from FY23 to FY26.
  2. Risk Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

Original filing on BSE

Metropolis Healthcare Limited Q1 FY27 results

As filed: Revenue ₹450 cr (+17% year on year), EBITDA ₹111 cr (+25% year on year), PAT ₹56.9 cr (+26% year on year), EBITDA margin 24.7% (+164 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹425 cr (+23% year on year), EBITDA ₹108 cr (+71% year on year), PAT ₹51.0 cr (+76% year on year), EBITDA margin 25.4% (+717 bps). Score 88 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 717 bps year on year. Share price after the results: −3.2% in 30 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹406 cr (+26% year on year), EBITDA ₹94.9 cr (+32% year on year), PAT ₹42.1 cr (+58% year on year), EBITDA margin 23.4% (+108 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit before exceptional items growth were well above the company's own trend. EBITDA margin rose 108 bps year on year. Revenue fell 5% from last quarter. Revenue rose ₹82.9 cr on a year ago, more than the ₹32.0 cr it added the year before. Share price after the results: −5.6% in 30 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹429 cr (+23% year on year), EBITDA ₹108 cr (+20% year on year), PAT ₹53.0 cr (+13% year on year), EBITDA margin 25.2% (−54 bps). Score 69 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin fell 54 bps year on year. Revenue rose ₹79.0 cr on a year ago, more than the ₹41.0 cr it added the year before. Share price after the results: −4.9% in 30 days (Nifty 500: +0.3%).
  • Q1 FY26: Revenue ₹386 cr (+23% year on year), EBITDA ₹89.0 cr (+11% year on year), PAT ₹45.0 cr (+18% year on year), EBITDA margin 23.1% (−250 bps). Score 74 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin fell 250 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +10.6% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹345 cr (+4% year on year), EBITDA ₹63.0 cr (−21% year on year), PAT ₹29.0 cr (−22% year on year), EBITDA margin 18.3% (−591 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 591 bps year on year. Profit fell 6% from last quarter. Share price after the results: +2.6% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹323 cr (+11% year on year), EBITDA ₹72.0 cr (+11% year on year), PAT ₹31.0 cr (+15% year on year), EBITDA margin 22.3% (−5 bps). Score 48 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin was flat year on year. Revenue fell 8% from last quarter.
  • Q2 FY25: Revenue ₹350 cr (+13% year on year), EBITDA ₹90.0 cr (+20% year on year), PAT ₹47.0 cr (+31% year on year), EBITDA margin 25.7% (+144 bps). Score 66 of 100, Above trend. EBITDA margin rose 144 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Metropolis Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.